Despite advances in management over recent years, epithelial ovarian cancer remains the most lethal gynaecological malignancy. As recurrence is common in advanced disease and efficacy of chemotherapeutic agents is limited, in this setting newer agent are very much in need. Promising newer cytotoxic agents are trabectidin, epothilones, canfosfamide, phenoxodiol and karenitecan. A number of newer targeted therapies, including vascular endothelial growth factor inhibitors, poly-ADP-ribose polymerase inhibitors and folate receptor inhibitors look promising. This chapter discusses the role of these newer agents.